Vivaldi Biosciences, Inc.

Private

Fort Collins, ColoradoHealthcare & Life Scienceshttps://vivaldibiosciences.com/

Last Round

Grant

Dec 18, 2023

Total Funding Raised

$33.64M

Company Overview

Vivaldi Biosciences, Inc. is a biotechnology company that develops intranasal vaccines for the protection against respiratory diseases using its proprietary Delta NS1 technology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

biotechnologynasal vaccineuniversal influenza vaccineviral vectorrespiratory diseasepandemic preparednessclinical-stage biotechgenetically engineered vaccineneedle-free vaccinedrug discoveryvaccine platformbiotech startupclinical trialsvaccine developmentnext-gen vaccines

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivaldi Biosciences, Inc. Comps

Public and private peers based on sector, stage, and business model.

Vivaldi Biosciences, Inc. comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vivaldi Biosciences, Inc. Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Dec 18, 2023
Grant	Jun 5, 2023
Series A	Jan 8, 2009
Debt	May 18, 2007

View all Funding Rounds

Key People

Founding team and executive leadership

Bill Wick

Chief Executive Officer, Director, Chief Operating Officer & Chief Financial Officer, Managing Director

Executive Team

Vivaldi Biosciences, Inc. Investors

Notable investors and investment history

Vivaldi Biosciences, Inc. investors
Investor	Rounds
Bay City Capital	Debt, Series A
Flu Lab	Grant
NGN Capital	Series A
European Union	Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 8, 2009
$23M round led by Bay City Capital and NGN Capital.

View all signals

Vivaldi Biosciences, Inc. Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Vivaldi Biosciences, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivaldi Biosciences, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersFort Collins, Colorado

Employee Range11

Year Founded2006

Last FundingDec 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.